Scilex Holding (SCLX) Convertible Debt (2021 - 2022)

Scilex Holding (SCLX) posted quarterly Convertible Debt of $2.0 million for Q3 2022, little changed on a QoQ basis from $2.0 million in Q2 2022.

Scilex Holding (SCLX) Convertible Debt (2021 - 2022) Analysis & Trends

Scilex Holding (SCLX) has reported Convertible Debt for 2 consecutive years, with $2.0 million the latest figure, recorded in Q3 2022.

In Q3 2022, Convertible Debt changed N/A year-over-year to $2.0 million; the TTM figure through Sep 2022 stood at $2.0 million (changed N/A YoY), while the FY2021 annual figure was $483099.0, changed N/A from the prior year.
Convertible Debt came in at $2.0 million for Q3 2022 at Scilex Holding, roughly flat from $2.0 million in the prior quarter.
The five-year high for Convertible Debt was $2.0 million in Q3 2022, with the low at $483099.0 in Q4 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Eli Lilly	1,066.16 Bn	1,060.88 Bn	16.22 Bn
2	Johnson & Johnson	611.69 Bn	589.64 Bn	15.96 Bn
3	AbbVie	444.34 Bn	434.99 Bn	10.78 Bn
4	Astrazeneca	284.94 Bn	277.05 Bn	12.61 Bn
5	Merck	224.23 Bn	218.58 Bn	12.09 Bn
6	Amgen	195.12 Bn	183.08 Bn	5.87 Bn
7	Gilead Sciences	156.45 Bn	148.73 Bn	5.52 Bn
8	Pfizer	136.01 Bn	123.24 Bn	-1.21 Bn
9	Novartis Ag	113.45 Bn	113.67 Bn	-
10	Scilex Holding	54.30 Mn	-95.62 Mn	4.15 Mn

Download Data